Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: SOUL, a randomized trial, design and baseline characteristics.
Darren K McGuireRodica P BusuiJohn DeanfieldCatherine M ViscoliJohannes F E MannNikolaus MarxSharon L MulvaghNeil PoulterMads D M EngelmannG Kees HovinghMaria Sejersten RipaMette GislumKirstine Brown-FrandsenJohn B BusePublished in: Diabetes, obesity & metabolism (2023)
SOUL will provide evidence regarding the CV effects of oral semaglutide in individuals with type 2 diabetes and established ASCVD and/or CKD. This article is protected by copyright. All rights reserved.